Discover an informative webinar on the benefits of uniting with a contract development and manufacturing organization (CDMO) for nucleic acid-based therapeutics production. The development and commercialization of nucleic acid-based therapeutics, including messenger RNA (mRNA), plasmid DNA (pDNA) and lipid nanoparticles (LNP) drug products, hold immense promise for revolutionizing healthcare. However, navigating the intricate landscape of their manufacturing processes poses significant challenges, often requiring coordination among multiple vendors.
This webinar explores the complexities inherent in managing diverse vendors for bioprocessing and emphasizes the benefits of consolidating operations with a single, integrated CDMO. Attendees of this event will gain insights into overcoming current program challenges while maximizing efficiency and product quality.
The webinar will also highlight key capabilities to seek out in an integrated CDMO guiding nucleic acid products from development through to commercial manufacturing, eliminating the need for multi-vendor coordination and ensuring robust supply chain continuity.
Key topics include leveraging a CDMO’s expertise, facilities and technology to optimize regulatory submissions, mitigate supply chain risks and enhance commercial manufacturing readiness. Attendees will learn how a unified approach from development to production can lower costs, reduce the risk of disruptions and expedite the progression of mRNA therapeutics from concept to market.
Register for this webinar to explore the advantages of consolidating manufacturing processes and discover how a singular, integrated approach can propel the advancement of mRNA manufacturing towards clinical success and widespread patient impact.
Speaker
Jessica Madigan, Director of Business Development, Nucleic Acid Modalities, BIOVECTRA
Jessica Madigan has a BSc in Chemistry with 15+ years of experience focused on nucleic acid manufacturing and development. Jessica played a key role at a start-up CDMO, leading to the successful launch of mRNA, plasmid, capping analogs and modified nucleotide products. Jessica also holds a Project Management Professional (PMP) Certification and successfully managed over 30 API manufacturing projects for mRNA early-phase clinical trials. Since joining BIOVECTRA in 2022, Jessica has supported business development efforts for pDNA, mRNA, LNP formulation and fill/finish services.
Message PresenterWho Should Attend?
This webinar will appeal to professionals in the following areas:
- CSO
- MSAT
- Tech Ops
- Quality assurance
- Category Managers
- CMC experts
What You Will Learn
Attendees will learn about:
- The benefits of consolidating mRNA manufacturing processes with a single, integrated CDMO to streamline operations, reduce supply chain complexity and minimize the risk of disruptions
- How partnering with an integrated CDMO eliminates the need for coordination among multiple vendors, optimizing regulatory submissions, mitigating risks and enhancing the readiness of mRNA products for market entry
- How a CDMO’s comprehensive solution offers cost savings, improved quality control and accelerated timelines, ultimately advancing the success and accessibility of mRNA therapies for patients worldwide
Xtalks Partner
BIOVECTRA
BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account